Literature DB >> 16236320

Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.

John P Houston1, Ilya A Lipkovich, Jonna Ahl, Matthew D Rotelli, Robert W Baker, Charles L Bowden.   

Abstract

UNLABELLED: A post hoc analysis of Young Mania Rating Scale (YMRS) item scores was conducted to identify symptoms that may predict impending relapse using prospectively collected data from a double-blind, randomized relapse prevention study of patients treated with olanzapine (N=200, 5-20 mg/d) versus lithium (N=201, 300-1800 mg/d).
METHODS: Relapses (YMRS > or = 15, or hospitalization) included in this analysis occurred 3-52 weeks after randomization. Repeated measures logistic regression of increases (> or = 1) in YMRS item scores prior to the visit that preceded relapse was used to estimate the odds of relapse.
RESULTS: A total of 31 patients relapsed during the first 3-16 weeks of the study (olanzapine, n=12; lithium, n=19). YMRS items that increased most frequently within a 2-week period preceding relapse were (olanzapine vs. lithium, respectively): increased motor activity/energy (58.3%, 21.1%), irritability (33.3%, 31.6%), decreased need for sleep (25.0%, 10.5%), increased speech (25.0%, 10.5%), and elevated mood (25.0%, 15.8%). YMRS items with significant odds ratios (OR) that predicted relapse in patients treated with olanzapine or lithium, respectively, were: increased motor activity/energy (OR, 35.7; OR, 7.8), irritability (OR, 9.5; OR, 7.8), elevated mood (OR, 8.1; OR, 4.2), and increased sexual interest (OR, 13.7; OR, 7.7).
CONCLUSIONS: Early recognition of symptom exacerbation in bipolar mania, particularly increased motor activity-energy may permit clinical interventions to help avert relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236320     DOI: 10.1016/j.jpsychires.2005.08.009

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

1.  Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study.

Authors:  John P Houston; Jennifer L Gatz; Elisabeth K Degenhardt; Hassan H Jamal
Journal:  BMC Res Notes       Date:  2010-11-02

2.  Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode.

Authors:  Christoph U Correll; Marta Hauser; Julie B Penzner; Andrea M Auther; Vivian Kafantaris; Ema Saito; Doreen Olvet; Ricardo E Carrión; Boris Birmaher; Kiki D Chang; Melissa P DelBello; Manpreet K Singh; Mani Pavuluri; Barbara A Cornblatt
Journal:  Bipolar Disord       Date:  2014-03-05       Impact factor: 6.744

3.  Olanzapine discontinuation emergent recurrence in bipolar disorder.

Authors:  Manu Arora; Samir Kumar Praharaj
Journal:  Indian J Psychol Med       Date:  2014-04

4.  Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta; Melina Siamouli; Marc Valenti; Stamatia Magiria; Timucin Oral; David Fresno; Panteleimon Giannakopoulos; George S Kaprinis
Journal:  Ann Gen Psychiatry       Date:  2007-10-09       Impact factor: 3.455

5.  Initial and relapse prodromes in adult patients with episodes of bipolar disorder: A systematic review.

Authors:  Nelson Andrade-González; Laura Álvarez-Cadenas; Jerónimo Saiz-Ruiz; Guillermo Lahera
Journal:  Eur Psychiatry       Date:  2020-02-12       Impact factor: 5.361

6.  Implementing machine learning in bipolar diagnosis in China.

Authors:  Yantao Ma; Jun Ji; Yun Huang; Huimin Gao; Zhiying Li; Wentian Dong; Shuzhe Zhou; Yue Zhu; Weimin Dang; Tianhang Zhou; Haiqing Yu; Bin Yu; Yuefeng Long; Long Liu; Gary Sachs; Xin Yu
Journal:  Transl Psychiatry       Date:  2019-11-18       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.